AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15855510 — intervention group
Group type: COMPARATOR
Intervention: 500 mg loading dose followed by 3,000 mg continuous infusion over 24 h
Number of subjects: 16
Study 15855510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion
Number of subjects: 16
Study 15855510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy as continuous infusion
Number of subjects: 16
Study 12791417 — intervention group
Group type: EXPERIMENTAL
Intervention: NN2211 (GLP-1 derivative), dose levels: eight, administered before glucose dose
Number of subjects: 0
Study 12791417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10445896 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management and community service reimbursement
Number of subjects: 5209
Study 10445896 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training and support group participation
Number of subjects: 5209
Study 10445896 — intervention group
Group type: COMPARATOR
Intervention: Medicare waiver reimbursement
Number of subjects: 5209
Study 7875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking analgesia followed by hypnotic analgesia
Number of subjects: 36
Study 7875920 — intervention group
Group type: COMPARATOR
Intervention: Waking analgesia followed by waking analgesia
Number of subjects: 36
Study 7875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia followed by waking analgesia
Number of subjects: 36
Study 2704510 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanic acid
Number of subjects: 152
Study 2704510 — intervention group
Group type: COMPARATOR
Intervention: clindamycin-gentamicin
Number of subjects: 152
Study 338081 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 338081 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 338081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30687908 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative vaginal erbium:YAG laser (VEL) treatment (20 min/session, thrice)
Number of subjects: 50
Study 30687908 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic agent (4 mg fesoterodine)
Number of subjects: 50
Study 30687908 — intervention group
Group type: COMPARATOR
Intervention: β3-adrenoceptor agonist (25 mg mirabegron)
Number of subjects: 50
Study 27866504 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal OXT
Number of subjects: 40
Study 27866504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support Services (TSS)
Number of subjects: 300
Study 26223696 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 300
Study 23650301 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypotensive therapy
Number of subjects: 367
Study 23650301 — intervention group
Group type: COMPARATOR
Intervention: No antihypotensive therapy
Number of subjects: 367
Study 21529354 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 77
Study 21529354 — intervention group
Group type: EXPERIMENTAL
Intervention: Visthesia
Number of subjects: 77
Study 19149837 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) - continuous 17-beta estradiol patch at 36 microg/day plus cyclic oral medroxyprogesterone acetate 2.5 mg/day for 12 days/month
Number of subjects: 22
Study 19149837 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 22
Study 19149837 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 17017752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic intervention (exercise, Ayurvedic diet, meditation instruction, Ayurvedic herb supplement MA 471)
Number of subjects: 60
Study 17017752 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes education classes with primary care clinician follow‐up (Control)
Number of subjects: 60
Study 12834197 — intervention group
Group type: EXPERIMENTAL
Intervention: CC atrophy in CDR 1 & 2 patients
Number of subjects: 170
Study 12834197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy in CDR 0.5 patients
Number of subjects: 170
Study 12834197 — intervention group
Group type: COMPARATOR
Intervention: Frontal executive dysfunction associated with CC atrophy
Number of subjects: 170
Study 12834197 — intervention group
Group type: COMPARATOR
Intervention: CC atrophy and WMH correlation
Number of subjects: 170
Study 12834197 — intervention group
Group type: COMPARATOR
Intervention: Combined effect of CC atrophy and WMH in verbal fluency test
Number of subjects: 170
Study 10873882 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysis with cuprammonium membrane
Number of subjects: 10
Study 10873882 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone membrane with acetate
Number of subjects: 10
Study 10873882 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysis with polysulfone membrane
Number of subjects: 10
Study 10873882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis with cuprammonium membrane
Number of subjects: 10
Study 10873882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis with polysulfone membrane
Number of subjects: 10
Study 10873882 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 9315426 — intervention group
Group type: EXPERIMENTAL
Intervention: Various HIV-related medications
Number of subjects: 71
Study 9315426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 71
Study 9315426 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label design
Number of subjects: 71
Study 9315426 — intervention group
Group type: COMPARATOR
Intervention: Trials published in journals of wide readership
Number of subjects: 71
Study 1535110 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for myocardial infarction (exact treatments not specified)
Number of subjects: 0
Study 1535110 — intervention group
Group type: COMPARATOR
Intervention: Review articles and textbook recommendations (control group)
Number of subjects: 0
Study 1535110 — intervention group
Group type: COMPARATOR
Intervention: Treatments with no effect on mortality or potentially harmful treatments (control group)
Number of subjects: 0
Study 4077377 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen protein (1.3 g/kg desirable body weight per day)
Number of subjects: 8
Study 4077377 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (1.3 g/kg desirable body weight per day)
Number of subjects: 8
Study 4077377 — intervention group
Group type: COMPARATOR
Intervention: Control (very-low-calorie diet without specifying protein source)
Number of subjects: 8
Study 29931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.05 mg/kg for 2 years
Number of subjects: 80
Study 29931143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl) for 2 years
Number of subjects: 80
Study 28937025 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 62
Study 28937025 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 62
Study 26374907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 80
Study 26374907 — intervention group
Group type: COMPARATOR
Intervention: Nasal Intermittent Positive-Pressure Ventilation (NIPPV)
Number of subjects: 80
Study 23279918 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI) in conjunction with Traditional Oral Health Education (TOHE) (n = 29)
Number of subjects: 56
Study 23279918 — intervention group
Group type: COMPARATOR
Intervention: Traditional Oral Health Education (TOHE) alone (n = 27)
Number of subjects: 56
Study 18723519 — intervention group
Group type: COMPARATOR
Intervention: Inhibited pacing (INH; basal rate 40 bpm/hysteresis 30 bpm; n = 38)
Number of subjects: 77
Study 18723519 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing with optimized atrioventricular delay (OPT; stimulation rate 65-120 bpm, n = 39)
Number of subjects: 77
Study 16749288 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary reperfusion therapy
Number of subjects: 0
Study 16749288 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0
Study 16749288 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic regimens adjusted for elderly patients
Number of subjects: 0
Study 14530670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologist grading of dysplasia
Number of subjects: 190
Study 14530670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologist grading of human papillomavirus status
Number of subjects: 190
Study 14530670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologist grading of quality of histology
Number of subjects: 190
Study 14530670 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete agreement between original pathology and pathologists
Number of subjects: 190
Study 14530670 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of 86 slides previously read by one pathologist
Number of subjects: 190
Study 11714046 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam (100/12.5 mg/kg every 8 h)
Number of subjects: 70
Study 11714046 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus Metronidazole (50/7.5 mg/kg every 8 h)
Number of subjects: 70
Study 11714046 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Number of subjects: 70
Study 11714046 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus Metronidazole
Number of subjects: 70
Study 9760818 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (Lipanthyl 200 m) for 1 month
Number of subjects: 10
Study 9760818 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 10
Study 7533224 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg b.i.d.)
Number of subjects: 26
Study 7533224 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 26
Study 3216030 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral tablet of dilevalol
Number of subjects: 12
Study 3216030 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous infusion of dilevalol
Number of subjects: 12
Study 31423686 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS + active PNFS
Number of subjects: 52
Study 31423686 — intervention group
Group type: COMPARATOR
Intervention: SCS + inactive PNFS
Number of subjects: 52
Study 29193419 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) supplementation (1,800 mg hydroalcoholic extract as four tablets per day)
Number of subjects: 50
Study 29193419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch, lactose, and avicel as four tablets per day)
Number of subjects: 50
Study 28139163 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Serum (AS)
Number of subjects: 0
Study 28139163 — intervention group
Group type: COMPARATOR
Intervention: Preservative Free Artificial Tear (PFAT)
Number of subjects: 0
Study 26767232 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope with channeled blade
Number of subjects: 50
Study 26767232 — intervention group
Group type: COMPARATOR
Intervention: Airtraq
Number of subjects: 50
Study 23278371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirasol-treated (MIR) PLT transfusions
Number of subjects: 12
Study 23278371 — intervention group
Group type: COMPARATOR
Intervention: Standard reference (REF) PLT transfusions
Number of subjects: 12
Study 21241207 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 8 weeks (q8w)
Number of subjects: 112
Study 21241207 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 12 weeks (q12w)
Number of subjects: 112
Study 21241207 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg every 8 weeks (q8w)
Number of subjects: 112
Study 21241207 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (various dosages) during the open-label extension (OLE)
Number of subjects: 112
Study 21241207 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (various dosages)
Number of subjects: 112
Study 17434171 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg pre-treatment
Number of subjects: 200
Study 17434171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no addition of 500 mg aspirin)
Number of subjects: 200
Study 16868496 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 40
Study 16868496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14765002 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavior Scale (FrSBe) for MS group
Number of subjects: 26
Study 14765002 — intervention group
Group type: COMPARATOR
Intervention: Frontal Systems Behavior Scale (FrSBe) for HC group
Number of subjects: 26
Study 14765002 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ratings and family ratings of behavioral changes
Number of subjects: 26
Study 14765002 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical disease progression
Number of subjects: 26
Study 10233210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1-2 g daily for up to 4 weeks)
Number of subjects: 56
Study 10233210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10233210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 56
Study 8712737 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + SOD 8 mgr/IM/day
Number of subjects: 448
Study 8712737 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 448
Study 1781870 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (1000 mg/day) or placebo
Number of subjects: 111
Study 1781870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (500 mg/day)
Number of subjects: 111
Study 1781870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine for primary or secondary prophylaxis
Number of subjects: 111
Study 1781870 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ counts less than or equal to 0.2 x 10(9)/l before 30 November 1988
Number of subjects: 111
Study 1781870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative numbers of AIDS cases among patients with sufficient CD4+ counts
Number of subjects: 111
Study 7082523 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg kg‐1
Number of subjects: 60
Study 7082523 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 3 mg kg‐1
Number of subjects: 60
Study 30944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised pneumoperitoneum pressure strategy
Number of subjects: 0
Study 30944044 — intervention group
Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum pressure strategy
Number of subjects: 0
Study 27923181 — intervention group
Group type: EXPERIMENTAL
Intervention: COC (1.5mg estradiol and 2.5mg nomegestrolacetate)
Number of subjects: 202
Study 27923181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 27923181 — intervention group
Group type: EXPERIMENTAL
Intervention: COC
Number of subjects: 202
Study 26466202 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1830
Study 26466202 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 1830
Study 23848416 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent assimilation
Number of subjects: 266
Study 23848416 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies between adolescent and parent family functioning reports
Number of subjects: 266
Study 21543293 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily for one month
Number of subjects: 20
Study 21543293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for one month
Number of subjects: 20
Study 21543293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18481715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at specific acupoints (contralateral scalp motor region, Jiquan (HT 1), Chize (LU 5), Daling (PC 7), Jianyu (LI 15), Tianjing (TE 10), Yangchi (TE 4)) for 3 weeks.
Number of subjects: 60
Study 18481715 — intervention group
Group type: COMPARATOR
Intervention: Electro-stimulation treatment for 3 weeks.
Number of subjects: 60
Study 16508254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 10
Study 16508254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 10
Study 16508254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meal
Number of subjects: 10
Study 12780463 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in psychiatry
Number of subjects: 0
Study 12780463 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy RCTs
Number of subjects: 0
Study 12780463 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized results of RCTs to clinical practice
Number of subjects: 0
Study 11126172 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 20
Study 11126172 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity and macular perimetric mean sensitivity
Number of subjects: 20
Study 8979203 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded nasal dilator
Number of subjects: 34
Study 8979203 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 34
Study 1816663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature of 32-33 degrees C
Number of subjects: 32
Study 1816663 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature of 22-23 degrees C
Number of subjects: 32
Study 6606404 — intervention group
Group type: EXPERIMENTAL
Intervention: Long cross‐clamp technique (Group 1)
Number of subjects: 91
Study 6606404 — intervention group
Group type: COMPARATOR
Intervention: Short cross‐clamp technique (Group 2)
Number of subjects: 91
Study 3490992 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-HU
Number of subjects: 24
Study 3490992 — intervention group
Group type: COMPARATOR
Intervention: HSA
Number of subjects: 24
Study 29660924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restrictive regimen with norepinephrine administration up to 0.04μg/kg/min (FRV)
Number of subjects: 0
Study 29660924 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid administration (LFA)
Number of subjects: 0
Study 26722003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 17387
Study 24941835 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder (YP) combined with routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Number of subjects: 156
Study 24941835 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Number of subjects: 156
Study 22512510 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Communication Intervention Project (SCIP)
Number of subjects: 88
Study 22512510 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 88
Study 20553601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 20553601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 0
Study 20553601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18254721 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week exercise training intervention (individualized cardiorespiratory and resistance exercise, 150 min of moderate-intensity exercise per week)
Number of subjects: 132
Study 18254721 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week exercise training intervention
Number of subjects: 132
Study 15968840 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cognitive-behavioural therapy (FCBT)
Number of subjects: 0
Study 12716807 — intervention group
Group type: EXPERIMENTAL
Intervention: Modem group (transmit blood glucose data every 2 weeks for 6 months)
Number of subjects: 70
Study 12716807 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care with quarterly clinic visits)
Number of subjects: 70
Study 10594471 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ RAD (0.25, 0.75, 2.5, 7.5, 15, 25 mg)
Number of subjects: 54
Study 10594471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10594471 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ RAD (2.5-25 mg)
Number of subjects: 54
Study 10594471 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ RAD (0.25-25 mg)
Number of subjects: 54
Study 8618008 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ 281‐240 (macrolide)
Number of subjects: 15
Study 8618008 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent halogenated corticosteroid
Number of subjects: 15
Study 8618008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2011703 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Senna laxative (X‐prep) combined with a saline enema (n = 88)
Number of subjects: 271
Study 2011703 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol electrolyte lavage solution (Golytely) (n = 90)
Number of subjects: 271
Study 2011703 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of Cascara‐Salax laxative (PicoSalax) and Golytely (n = 93)
Number of subjects: 271
Study 2011703 — intervention group
Group type: COMPARATOR
Intervention: Regimen II (Golytely)
Number of subjects: 271
Study 2011703 — intervention group
Group type: COMPARATOR
Intervention: Outpatients
Number of subjects: 271
Study 7073570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin administration before and after surgery
Number of subjects: 0
Study 7073570 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 7073570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 0